In the last three months, 6 analysts have published ratings on Avidity Biosciences RNA, offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target of $39.67, a high estimate of $60.00, and a low estimate of $33.00. This current average has increased by 15.55% from the previous average price target of $34.33.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Avidity Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | $35.00 |
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | $35.00 |
| Keay Nakae | Chardan Capital | Maintains | Buy | $33.00 | $33.00 |
| Geoff Meacham | B of A Securities | Announces | Buy | $40.00 | - |
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | - |
| Eric Schmidt | Cantor Fitzgerald | Announces | Overweight | $60.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Avidity Biosciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Avidity Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Avidity Biosciences analyst ratings.
All You Need to Know About Avidity Biosciences
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Avidity Biosciences: Delving into Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Avidity Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 58.67% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Avidity Biosciences's net margin excels beyond industry benchmarks, reaching -1943.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Avidity Biosciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.34%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.72%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
The Basics of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
